Group 1: Company Overview and Investment Strategy - The company aims to expand its scale through mergers and acquisitions, primarily focusing on the pharmaceutical industry for suitable targets [2] - Future prescription drug markets are expected to remain constrained, prompting the company to consider development in OTC and health sectors, including prevention and rehabilitation [2] - The company seeks to invest in advantageous products or acquire equity stakes in companies with high net profit margins [2] Group 2: Financial Management - Idle funds are mainly used for purchasing bank principal-protected financial products, with financing needs dependent on the availability of investment projects and their actual funding requirements [2] Group 3: Marketing Strategy - The current sales model combines agents with refined marketing, with essential drug provinces like Shandong, Henan, and Yunnan contributing approximately 30% to sales [3] - Each provincial area has a market manager supported by 1-2 academic specialists, and the company plans to expand its marketing team by learning from successful practices of other companies [3]

Group 1: Market Position and Product Overview - The market share of the injection product "Dengzhanhua" is approximately 1.99% in the cardiovascular traditional Chinese medicine market, with hospital coverage at only 15% to 20%, indicating significant growth potential despite a slowing growth rate [2]. - The overall market size for "Dengzhanhua" preparations is around 2.5 billion CNY [2]. - The company focuses on a single-component formulation of "Dengzhanhua," differentiating it from competitors who offer multi-component products [3]. Group 2: Pricing and Tendering Process - Currently, only a few provinces have completed the drug tendering process, with the announced tender prices for "Dengzhanhua" showing a decline [2]. - The company plans to enhance market promotion efforts to mitigate the impact of price reductions resulting from the tendering process [2]. - 2016 is identified as a significant year for tendering, with expectations that the tendering work will conclude in 2017 [2]. Group 3: Research and Development - The company has completed the collection of 30,000 clinical samples for the safety evaluation of "Dengzhanhua," with preliminary results expected by June 2017 [3]. - Ongoing research includes the development of new formulations and enhancing the bioavailability of "Dengzhanhua" through innovative delivery methods [3]. - The company is also exploring diversification in its product line, including new drugs targeting pancreatic cancer and stroke [3]. Group 4: Marketing Strategy and Sales - The sales model combines agents with refined marketing, with essential drug provinces accounting for approximately 30% of sales [4]. - The company plans to expand its marketing team and focus on grassroots hospitals to increase sales volume significantly [4]. - The implementation of the "two-invoice system" has increased financial personnel and operational costs, but the impact on net profit is expected to be minimal due to increased sales [4]. Group 5: Safety and Efficacy - Clinical trials involving 104 patients showed no significant adverse effects from "Dengzhanhua," confirming its safety profile [17]. - The drug has demonstrated significant efficacy in improving blood flow dynamics and microcirculation in patients with cardiovascular diseases [22][26]. - Research indicates that "Dengzhanhua" can effectively treat acute ischemic conditions and improve neurological function in stroke patients [30].

Group 1: Market Overview - The market share of the current herbal medicine products related to "Deng Zhan Hua" is approximately 1.99%, with hospital coverage only at 15% to 20%, indicating significant potential for future market expansion [3] - The main competitors in the "Deng Zhan Hua" product segment are Longjin Pharmaceutical, Hunan Hengsheng, and Biovale, although they produce different formulations [3] Group 2: Product Confidence and Quality Control - The company's confidence in its products stems from strict quality control measures, including advanced equipment and meticulous processes from cultivation to packaging [3] - The company adheres to national new drug application standards, conducting pharmacological and toxicological research, and has completed clinical phase IV safety and efficacy evaluations [3] Group 3: Product Positioning and Marketing - The injectable "Deng Zhan Hua" product is currently included in the national medical insurance catalog but has not yet entered the national essential drug list; it is included in local essential drug supplements in Yunnan, Shandong, and Henan [4] - The marketing strategy primarily focuses on academic promotion, with provincial managers and agents working in tandem, supported by a team of experts conducting nationwide academic training [4] Group 4: Financial Performance and Goals - The company's revenue target for the year aligns with the third-quarter report, with a projected fluctuation of approximately 10% to 60% [4] - The profit growth reported in the third quarter is mainly attributed to the disposal of subsidiary investments and increased returns from financial products [4] Group 5: Strategic Decisions - The company has decided to transfer all equity of its subsidiary Beijing Kechuang due to its low relevance to the main business and the high costs associated with necessary upgrades to meet market demands [5]

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2016-002 | --- | --- | --- | --- | |-------------------------|------------------------------------|----------------------------|--------------------------------------------------------| | | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | | 类别 | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | ■现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 东方证券 陈宇哲 | | | | 时间 | 2016 年 08 月 25 日 11 | 时 — 14 时 | | | 地点 | 本公司 | | | | 接待人员姓名 | 董事会秘书 李亚鹤 | | | | | 一、现场参观 | | | | | 董事会 ...

1 证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2017-008 | --- | --- | --- | |----------------|-----------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 中信证券股份有限公司 | 白梓玥 | | 人员姓名 | 鹏华基金管理有限公司 | 袁航、伍璇、陈圆明 | | 时间 | 2017 年 9 月 5 日 10 时 | 30 分 —12 时 | | 地点 | 本公司 | | | 接待人员姓名 | 董事会秘书 李亚鹤 证券事务代表 宁博 | | | | 一、现场参观 | | | | | 公司领导陪同来访者观看公司 ...

1 证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2017-007 | --- | --- | --- | --- | |----------------|--------------------------------------------------|--------------|--------------------------------------------------------| | | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称及 | 上海庚荣投资管理有限公司 | 李臻 | 副总裁 | | 人员姓名 | | 王锐 | 投资总监 | | | | 肖杨 | 总裁助理 | | 时间 | 2017 年 7 月 11 日 10 时 — | 时 30 分 | | | 地点 | 本公司 | | | | 接待人员姓名 | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥78,111,085.92, a decrease of 80.35% compared to ¥397,538,178.27 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥2,466,794.53, representing a decline of 150.62% from a profit of ¥4,872,911.81 in the previous year[21]. - The basic and diluted earnings per share were both -¥0.0062, down 150.82% from ¥0.0122 in the previous year[21]. - The total profit for the first half of 2022 was CNY -2,386,786.57, contrasting with a profit of CNY 836,000.86 in the same period of 2021[146]. - The total comprehensive income for the first half of 2022 was CNY -4,476,714.96, compared to CNY 2,350,275.53 in the same period of 2021[147]. - The company reported a significant increase in other income, which rose to CNY 2,744,217.22 from CNY 1,458,122.86 in the previous year[146]. - The company reported a net profit of 51,184,636.37 million yuan for the first half of 2022, reflecting a decline of 2.4% year-over-year[158]. Cash Flow and Assets - The net cash flow from operating activities improved by 28.78%, with a net outflow of ¥18,144,628.18 compared to ¥25,475,931.67 in the same period last year[21]. - The net cash flow from investing activities increased by 255.86% to ¥32,727,521.11 from -¥20,997,356.40, due to changes in cash management products and reduced long-term asset expenditures[44]. - The company's cash and cash equivalents increased by 158.98% to ¥14,582,892.93 from -¥24,724,909.83, driven by improved cash flow from operating and investing activities[44]. - Cash and cash equivalents increased to 116,621,556.66, making up 14.48% of total assets, up from 12.33% the previous year, due to changes in cash management product balances[50]. - The company's total current assets as of June 30, 2022, amounted to 510,419,931.59 yuan, a decrease from 522,766,802.94 yuan at the beginning of the year[137]. - The total assets of the company reached 400.5 million yuan, with a significant portion allocated to other equity instruments amounting to 112.7 million yuan[165]. Research and Development - The company plans to enhance its R&D capabilities and develop high-end generic drugs and innovative medications targeting cardiovascular and metabolic diseases[34]. - The R&D investment has consistently accounted for 10% of sales revenue, with over 60 products in the chemical generic drug development pipeline, and a dedicated R&D team of approximately 60 members[38]. - Research and development expenses increased to CNY 10,396,507.32, up 47.5% from CNY 7,040,165.79 in the previous year[146]. - The company has submitted a new drug clinical trial application for its innovative drug ZKLJ02, aimed at treating strokes, which has been accepted by NMPA[35]. Market and Sales - The company experienced a substantial decline in revenue and product sales due to hospital prescription restrictions and policy impacts, resulting in a shift from profit to loss for the reporting period[34]. - The company’s participation in centralized procurement led to a price drop of approximately 67% for its products, adversely affecting sales volume and revenue in both procurement and non-procurement regions[34]. - The marketing system has been established to cover all drug categories and channels, with a presence in all 30 provinces, ensuring effective market access and sales support[41]. - The company is focusing on optimizing its quality management system and enhancing its production management to reduce unit costs of core products[36]. Risks and Challenges - The company faced significant uncertainties regarding future performance due to market conditions and operational efforts[4]. - The company is facing risks from industry policy changes, with significant impacts on sales and performance due to stricter regulations and price controls, particularly affecting traditional Chinese medicine and chemical generic drugs[66]. - There is a risk of goodwill and asset impairment due to the performance of subsidiaries not meeting expectations, which could adversely affect the company's overall performance[71]. - The company has identified management risks due to the expansion of its business and workforce, which may lead to challenges in maintaining effective management and internal controls[68]. Corporate Governance and Compliance - The company has maintained a transparent communication strategy with regulatory authorities to ensure accurate and timely information disclosure[83]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[88]. - The financial report was approved by the board of directors on August 25, 2022[173]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[177]. Future Outlook - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[157]. - Future guidance indicates a focus on market expansion and potential mergers and acquisitions to drive growth[165]. - The company aims to improve its operational efficiency through technological advancements and strategic partnerships in the upcoming quarters[157].

Financial Performance - The company's revenue for Q1 2022 was ¥47,566,231.83, a decrease of 76.92% compared to ¥206,120,330.21 in the same period last year[5] - Net profit attributable to shareholders was ¥832,287.46, down 68.43% from ¥2,636,189.61 year-on-year[5] - The total operating revenue for the first quarter was CNY 47,566,231.83, a significant decrease from CNY 206,120,330.21 in the previous period[29] - The net profit for the first quarter of 2022 was CNY 689,639.58, a decrease of 42.9% compared to CNY 1,207,677.17 in the same period of the previous year[32] - The total profit for the first quarter was CNY 1,391,705.62, up from CNY 462,827.63, indicating a significant increase[32] - The operating profit for the first quarter was CNY 1,395,528.98, compared to CNY 463,595.64 in the previous year, showing a substantial improvement[32] - The company reported a basic and diluted earnings per share of CNY 0.0021, down from CNY 0.0066 in the same period last year[32] - The company experienced a decrease in sales revenue from CNY 139,970,046.70 to CNY 54,659,735.81 in the first quarter[33] - The total comprehensive income for the first quarter was CNY 689,639.58, compared to CNY 1,207,677.17 in the previous year[32] Cash Flow and Liquidity - The net cash flow from operating activities improved by 67.97%, reaching -¥10,187,664.02 compared to -¥31,810,151.06 in the previous year[11] - The cash flow from operating activities was negative at CNY -10,187,664.02, an improvement from CNY -31,810,151.06 in the previous year[34] - Cash and cash equivalents decreased from CNY 102,038,663.73 at the beginning of the year to CNY 87,288,618.35 by March 31, 2022[25] - Cash and cash equivalents at the end of the period were CNY 87,288,618.35, down from CNY 131,569,109.02 at the end of the previous year[35] - The cash inflow from investment activities was CNY 217,193,317.64, while cash outflow was CNY 221,755,699.00, resulting in a net cash flow of CNY -4,562,381.36[34] Assets and Liabilities - The company's total assets decreased by 1.21% to ¥817,236,417.04 from ¥827,279,853.47 at the end of the previous year[5] - The total assets as of March 31, 2022, were CNY 817,236,417.04, down from CNY 827,279,853.47 at the beginning of the year[28] - The total liabilities decreased from CNY 148,985,664.02 at the beginning of the year to CNY 138,252,588.01 by March 31, 2022[27] - The company’s total equity as of March 31, 2022, was CNY 678,983,829.03, slightly up from CNY 678,294,189.45 at the beginning of the year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,678[13] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 40.58% of shares, totaling 162,504,262 shares, with 27,000,000 shares pledged[13] - The second largest shareholder, Lixing Industrial Co., Ltd., holds 19.18% of shares, totaling 76,824,043 shares[13] Research and Development - Research and development expenses decreased by 29.20% to ¥3,865,773.86 from ¥5,459,852.75 year-on-year[10] - Research and development expenses for the first quarter were CNY 3,865,773.86, down from CNY 5,459,852.75 in the previous period[29] - The company did not report any new product launches or technological advancements during this quarter[5] - The company has not disclosed any new product or technology developments in the current report[18] Subsidiary and Equity Transfers - The company has transferred the equity of its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., in October 2021, which significantly impacted revenue and cost figures[10] - The company has completed the transfer of 51% equity in its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., for a total price of 37,336,000 RMB[20] - The company has provided guarantees for its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., with a total guarantee amount of up to 25 million RMB[18] - As of March 31, 2022, the guarantee balance for Yunnan Longjin Pharmaceutical Sales Co., Ltd. is 24,994,000 RMB[21] - The company has not yet signed a profit compensation agreement with the original shareholders of Muya Agriculture regarding the performance shortfall[23] Legal and Procurement Issues - The company is currently involved in a legal dispute regarding the validity of a share transfer contract, which may impact future profits[16] - The company participated in a centralized procurement for traditional Chinese medicine, with a proposed winning price of 75.31 RMB per box, representing a 67% decrease from the current procurement price[15] - The company has not signed any procurement documents related to the centralized procurement, leading to uncertainty in expected procurement volume and actual sales[15] Investment Income - The company recorded a decrease in investment income by 28.04%, amounting to ¥1,522,721.95 compared to ¥2,115,982.24 in the previous year[11] - The company reported a significant increase in investment income from joint ventures, with losses of CNY -159,893.11 compared to CNY -141,687.20 in the previous year[32]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the previous year[14]. - The company's operating revenue for 2021 was ¥702,518,674.54, representing a 176.55% increase compared to ¥254,026,717.66 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥3,093,411.14, a decrease of 73.81% from ¥11,811,617.50 in 2020[20]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[145]. - The company provided a revenue guidance of 1.8 billion yuan for the next fiscal year, which would represent a growth of 20%[132]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[132]. - The company reported a net profit of 3.0934 million yuan in 2021, a decrease of 73.81% compared to 11.8116 million yuan in 2020[54]. Research and Development - The company plans to invest RMB 100 million in R&D for new drug development in 2022, focusing on innovative therapies[14]. - The company has established a research and development team of approximately 60 people, with R&D investment accounting for over 10% of sales revenue[43]. - The company has initiated several R&D projects, including the submission of an ANDA application for a cardiovascular drug injection, which is expected to enhance its competitive edge[79]. - R&D investment increased by 20.49% to ¥24,950,735.61 in 2021, while the proportion of R&D investment to operating income decreased to 3.55% from 8.15% in 2020[80]. - The company is actively developing high-end chemical generics and innovative drugs, but faces risks related to long development cycles and regulatory challenges[113]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2025[14]. - Future guidance estimates a revenue growth of 12% to 15% for 2022, driven by new product launches and market expansion[14]. - The company is focusing on expanding its product offerings and enhancing production capacity through ongoing R&D efforts, particularly in chemical generic and innovative drug development[79]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[145]. - Market expansion plans include entering three new provinces, projected to increase market share by 15%[132]. Product Development and Launches - The company has successfully launched two new products in Q4 2021, contributing to a 5% increase in market share[14]. - New product launches are expected to contribute an additional 300 million yuan in revenue over the next year[132]. - The company is committed to accelerating the market launch of new products, including injection products LJ201801 and LJ201802, and aims to obtain NMPA production approvals[110]. Challenges and Risks - The company faces challenges due to a 67% price reduction on related products from the implementation of centralized drug procurement, impacting revenue and sales stability[31]. - The company faces risks from policy changes, which could negatively impact sales and pricing of major products[111]. - The company’s profitability is vulnerable due to reliance on cash management investment income and government subsidies, which may decline[116]. - The company faces risks related to goodwill and asset impairment due to the increasing number of subsidiaries and potential underperformance of these subsidiaries, which could adversely affect future net profits[117]. Corporate Governance and Management - The company has established a robust investor relations management system to ensure timely and accurate information disclosure to investors[124]. - The company has a complete and independent financial management system, with no interference from the controlling shareholder in financial decisions[127]. - The board of directors held a total of 7 meetings during the reporting period, with all resolutions passed unanimously[149]. - The company has established a talent cultivation system, including the "Dragon Plan" for nurturing backup talents, aimed at enhancing management and work skills[157]. Compliance and Internal Controls - The company has maintained compliance with national laws and regulations, with no major violations reported in the last three years[169]. - The internal control evaluation report indicates that all evaluated units accounted for 100% of the company's total assets and revenue[163]. - The company has implemented a comprehensive internal control system to protect the rights of shareholders and creditors[169]. - There were no significant internal control deficiencies reported during the fiscal year[162]. Employee and Social Responsibility - Employees are provided with five types of social insurance and housing fund as per national regulations[169]. - The company actively engages in social responsibility initiatives, including donations to disaster areas, with a market value of CNY 385,800 for donated medicines[171]. - The company has established sports facilities, such as a basketball court, to enhance employees' recreational activities[169]. Future Commitments and Shareholder Relations - The company has committed to ensuring compliance with stock purchase plans by newly appointed directors and senior management[182]. - The company will strictly fulfill its commitments made in the IPO prospectus, and if any commitments are not fulfilled, it will take measures such as public explanation and compensation to investors[180]. - The company will implement stock price stabilization measures if its stock price closes below the audited net asset value per share for 20 consecutive trading days[181].

Revenue and Profitability - The company's revenue for the third quarter reached ¥196,270,919, representing a 207.25% increase year-over-year[3] - Net profit attributable to shareholders was ¥1,699,775.47, a decrease of 56.32% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was -¥835,789.50, reflecting a decline of 368.07% year-over-year[3] - The company's basic earnings per share were ¥0.0042, down 56.25% compared to the same period last year[3] - The net profit for the period was impacted by a credit impairment loss of CNY 4,555,612.37, compared to a gain of CNY 316,283.12 in the previous period[20] - The net profit for the third quarter of 2021 was CNY 3,269,778.96, a significant recovery from a net loss of CNY -3,225,437.92 in the same period last year[21] - The total comprehensive income attributable to the parent company was CNY 6,572,687.28, compared to CNY 2,284,709.88 in the previous year[22] - The company reported a total revenue of CNY 2,475,384.25 in operating profit, a turnaround from a loss of CNY -1,581,423.23 in the same quarter last year[21] - The basic and diluted earnings per share were both CNY 0.0164, compared to CNY 0.0057 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,045,633,281.48, an increase of 24.22% from the end of the previous year[3] - The total assets of the company increased to CNY 1,045,633,281.48 from CNY 841,755,807.01, reflecting a growth of about 24.2%[20] - The total liabilities rose to CNY 324,268,954.99 from CNY 137,049,500.13, indicating an increase of approximately 136.5%[19] - Total liabilities reached approximately 137.05 million, with current liabilities at 100.28 million and non-current liabilities at 36.77 million[30] - Owner's equity totaled approximately 704.71 million, with 636.05 million attributable to the parent company[30] Cash Flow and Financial Activities - The company reported a net cash flow from operating activities of -¥17,984,576.38, a significant decline of 675.24% year-to-date[3] - The net cash flow from operating activities decreased significantly to -CNY 17.98 million, a decline of 675.24% year-on-year[9] - The company experienced a 31.23% decrease in net cash flow from financing activities, amounting to CNY 21.40 million[9] - The cash flow from investment activities showed a net outflow of CNY -33,938,504.58, improving from CNY -53,007,915.95 in the previous year[25] - The company recorded a total operating cash outflow of CNY 558,243,219.88, compared to CNY 202,680,134.11 in the previous year[25] Accounts Receivable and Inventory - Accounts receivable increased by 163.66% to ¥115,797,092.54 due to increased sales activities[8] - Inventory rose by 151.54% to ¥137,521,413.85, attributed to increased stock levels at the subsidiary[8] - Accounts receivable surged to CNY 115,797,092.54, up from CNY 43,919,037.39, marking an increase of around 163.5%[18] - Inventory levels rose significantly to CNY 137,521,413.85 from CNY 54,671,128.80, which is an increase of approximately 151.1%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,866[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 41.38% of the shares, totaling 165,723,830 shares[11] Legal and Compliance Issues - The company is involved in a legal dispute regarding the validity of a share transfer contract, which may impact its operations[13] - The report for the third quarter of 2021 was not audited, indicating potential limitations in the reliability of the financial data presented[32] Research and Development - Development expenditures increased by 33.87% to ¥19,383,786.74, driven by the progress of cardiovascular generic drug LJ201801[8] - Research and development expenses decreased by 29.43% to CNY 11.55 million, indicating reduced spending on new drug development[9] Other Financial Metrics - The company confirmed a significant increase in accounts payable, which rose by 768.92% to CNY 132.75 million[9] - The company recognized a right-of-use asset and lease liability due to the new leasing standards, impacting the financial statements[31] - The company has a deferred income tax asset of approximately 7.30 million, which may provide future tax benefits[29] - The company maintained a stable capital reserve of approximately 112.77 million, reflecting consistent financial management practices[30]